Find Research Projects

Search results

• Protocol No.: 1004201; Clinical Evaluation of the Actim Partus

  Pacheco, L.

  3/26/12 → 12/29/13

  Project: Other project

• Protocol No.: 10-720; Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy; Site No. 27364

  Silva, M.

  12/4/12 → 12/4/16

  Project: Other project

• Protocol No.: 10-720; Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy; Site No. 27364

  Silva, M.

  Abbott Vascular Incorporated

  12/4/12 → 12/4/16

  Project: Other project

• Protocol No.: 10-720; Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy; Site No. 27364

  Silva, M.

  Abbott Vascular Incorporated

  12/4/12 → 12/4/16

  Project: Other project

• Protocol No.: 10-720; Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy; Site No. 27364

  Silva, M.

  12/4/12 → 12/4/16

  Project: Other project

• Protocol No.: 11VR1.1; A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults with Growth Hormone Deficiency

  Urban, R.

  10/21/11 → 10/20/13

  Project: Other project

• Protocol No.: 11VR1.1; A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults with Growth Hormone Deficiency

  Urban, R.

  10/21/11 → 10/20/13

  Project: Other project

• Protocol No.: AB06012; A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, Phase 2b/3 study to compare efficacy and safty of masitinib at 3 and 6 mg/kg/day to methotrexate, with a randomi

  Gonzalez, E.

  3/4/11 → 2/28/16

  Project: Other project

• Protocol No.: AB06012; A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, Phase 2b/3 study to compare efficacy and safty of masitinib at 3 and 6 mg/kg/day to methotrexate, with a randomi

  Gonzalez, E.

  3/4/11 → 2/28/16

  Project: Other project

• Protocol No.: GB27862; "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma Who are on Inhaled Corticosteriods and a Second Controller Medication"

  Calhoun, W.

  5/16/12 → 5/15/14

  Project: Other project

• Protocol No.: GB27862; "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma Who are on Inhaled Corticosteriods and a Second Controller Medication"

  Calhoun, W.

  Genentech Inc.

  5/16/12 → 5/15/14

  Project: Other project

• Protocol No.: GB27862; "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma Who are on Inhaled Corticosteriods and a Second Controller Medication"

  Calhoun, W.

  5/16/12 → 5/15/14

  Project: Other project

• Protocol No.: I1Q-MC-JDDJ; Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 VersusPlacebo in Older Patents who fell recently and havemuscle weakness. The Study compound is Anti-Myostatin Antibody

  Volpi, E.

  4/10/12 → 4/10/14

  Project: Other project

• Protocol No.: I1Q-MC-JDDJ; Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 VersusPlacebo in Older Patents who fell recently and havemuscle weakness. The Study compound is Anti-Myostatin Antibody

  Volpi, E.

  Eli Lilly & Company

  4/10/12 → 4/10/14

  Project: Other project

• Protocol No.: I1Q-MC-JDDJ; Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 VersusPlacebo in Older Patents who fell recently and havemuscle weakness. The Study compound is Anti-Myostatin Antibody

  Volpi, E.

  4/10/12 → 4/10/14

  Project: Other project

• Protocol No.: IM103076; Evaluating Nulojix Long Term Safety in Transplant, ENLIST Study: 203387

  Cicalese, L.

  6/13/12 → 6/12/16

  Project: Other project

• Protocol No.: IM103076; Evaluating Nulojix Long Term Safety in Transplant, ENLIST Study: 203387

  Cicalese, L.

  6/13/12 → 6/12/14

  Project: Other project

• Protocol No.: IM103076; Evaluating Nulojix Long Term Safety in Transplant, ENLIST Study: 203387

  Cicalese, L.

  Bristol-Myers Squibb Company

  6/13/12 → 6/12/16

  Project: Other project

• Protocol No.: LCD-CDAD-11-06; "A Randomized Double-Blinded, Active-Controlled Study of CB-183,315 In Patients With Clostridium Difficile Associated Diarrhea"

  Parupudi, S.

  INC Research

  3/13/12 → 8/31/19

  Project: Other project

• Protocol No.: LCD-CDAD-11-06; "A Randomized Double-Blinded, Active-Controlled Study of CB-183,315 In Patients With Clostridium Difficile Associated Diarrhea"

  Parupudi, S.

  3/13/12 → 8/31/19

  Project: Other project

• Protocol No.: LCD-CDAD-11-06; "A Randomized Double-Blinded, Active-Controlled Study of CB-183,315 In Patients With Clostridium Difficile Associated Diarrhea"

  Parupudi, S.

  6/28/16 → 8/31/19

  Project: Other project

• Protocol No.: RDEA594-301; A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout

  Gonzalez, E.

  6/20/12 → 6/19/14

  Project: Other project

• Protocol No.: RDEA594-301; A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout

  Gonzalez, E.

  6/20/12 → 6/19/14

  Project: Other project

• Protocol No.: RDEA594-301; A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout

  Gonzalez, E.

  Ardea Biosciences

  6/20/12 → 6/19/14

  Project: Other project

• Protocol No.: V221-027; A Phase III Double-Blind, Randomized, Multicenter, Contgrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with Alternative Manufacturing Process (AMP)

  Rupp, R.

  6/21/12 → 6/20/14

  Project: Other project

• Protocol No.: V221-027; A Phase III Double-Blind, Randomized, Multicenter, Contgrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with Alternative Manufacturing Process (AMP)

  Rupp, R.

  Merck Sharp & Dohme Corporation

  6/21/12 → 6/20/14

  Project: Other project

• Protocol No.: V221-027; A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with Alternative Manufacturing Process (AMP)

  Rupp, R.

  6/21/12 → 6/20/14

  Project: Other project

• Protocol No.: V503-003-00-0255: "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillornavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year Old Men and 16- to 26-Year Old Women"

  Rupp, R.

  Merck Sharp & Dohme Corporation

  1/3/13 → 1/2/15

  Project: Other project

• Protocol No.: V503-003-00-0255: "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillornavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year Old Men and 16- to 26-Year Old Women"

  Rupp, R.

  1/3/13 → 1/2/15

  Project: Other project

• Protocol No.: V503-003-00-0255: "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillornavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year Old Men and 16- to 26-Year Old Women"

  Rupp, R.

  1/3/13 → 1/2/15

  Project: Other project

• Protocol No.: V59P23; "A Phase 3b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants"

  Rupp, R.

  4/27/12 → 4/26/14

  Project: Other project

• Protocol No.: V59P23; "A Phase 3b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants"

  Rupp, R.

  4/27/12 → 4/26/14

  Project: Other project

• Protocol No.: V59P23; "A Phase 3b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants"

  Rupp, R.

  Novartis Vaccines & Diagnostics Inc

  4/27/12 → 4/26/14

  Project: Other project

• Protocol No. 09DY02-17TNI-02: Alinity I STAT hsTnI Design Validation Protocol

  Okorodudu, A.

  11/6/18 → 11/5/21

  Project: Other project

• Protocol No. 09DY02-17TNI-02: Alinity I STAT hsTnI Design Validation Protocol

  Okorodudu, A.

  Abbott Laboratories

  11/6/18 → 11/5/21

  Project: Other project

• Protocol No. 771-0010: "A PMA Post-Approval Study to Evaluate the Long-Term Safety and Effectiveness of the Ovation/Ovation Prime Abdominal Stent Graft System"

  Silva, M.

  12/18/13 → 12/17/20

  Project: Other project

• Protocol No. 771-0010: "A PMA Post-Approval Study to Evaluate the Long-Term Safety and Effectiveness of the Ovation/Ovation Prime Abdominal Stent Graft System"

  Silva, M.

  12/18/13 → 12/17/20

  Project: Other project

• Protocol No. 771-0010: "A PMA Post-Approval Study to Evaluate the Long-Term Safety and Effectiveness of the Ovation/Ovation Prime Abdominal Stent Graft System"

  Silva, M.

  TriVascular Inc

  12/18/13 → 12/17/20

  Project: Other project

• Protocol No. ARQ197-A-U303 entitled "A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy"

  Cicalese, L.

  3/22/13 → 5/1/16

  Project: Other project

• Protocol No. ARQ197-A-U303 entitled "A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy"

  Cicalese, L.

  3/22/13 → 4/30/16

  Project: Other project

• Protocol No. ARQ197-A-U303 entitled "A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy"

  Cicalese, L.

  Daiichi Sankyo

  3/22/13 → 5/1/16

  Project: Other project

• Protocol No. C5261001: A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza in Healthy Individuals

  Rupp, R.

  1/1/00 → 1/1/00

  Project: Other project

• Protocol No. CA 0137: "Tack Optimized Balloon Angioplasty Clinical Trial for the Below the Knee Arteries Using the Tack Endovascular System (TOBA II-BTK)

  Silva, M.

  12/8/17 → 12/31/21

  Project: Other project

• Protocol No. CA 0137: "Tack Optimized Balloon Angioplasty Clinical Trial for the Below the Knee Arteries Using the Tack Endovascular System (TOBA II-BTK)

  Silva, M.

  12/8/17 → 12/31/21

  Project: Other project

• Protocol No. CA 0137: "Tack Optimized Balloon Angioplasty Clinical Trial for the Below the Knee Arteries Using the Tack Endovascular System (TOBA II-BTK)

  Silva, M.

  Intact Vascular

  12/8/17 → 12/31/21

  Project: Other project

• Protocol No. D3086-09-1: ACCU-CHEK Inform II Arterial Blood Evaluation Using Freedom 7 mm Test Strips

  Okorodudu, A.

  Roche Diagnostics

  3/18/09 → 3/17/16

  Project: Other project

• Protocol No. D3086-09-1: ACCU-CHEK Inform II Arterial Blood Evaluation Using Freedom 7 mm Test Strips

  Okorodudu, A.

  3/18/09 → 3/17/16

  Project: Other project

• Protocol No. L9040-09-2: Design Validation ACCU-CHECK Aviva and ACCU-CHECK Advantage Neonatal Blood Evaluation

  Okorodudu, A.

  8/21/09 → 8/20/16

  Project: Other project

• Protocol No. L9040-09-2: Design Validation ACCU-CHECK Aviva and ACCU-CHECK Advantage Neonatal Blood Evaluation

  Okorodudu, A.

  Roche Laboratories Inc.

  8/21/09 → 8/20/16

  Project: Other project

• Protocol No. V59P13E1: A Phase 3, Open-Label,Multi-Center Study to Evaluate the Persistence of Novartis MenACWY Antibody Response in Adolescents who Have Previously received either Novartis MenACWY Conjugate Vaccine or Menactra

  Rupp, R.

  2/2/09 → 2/1/15

  Project: Other project